Literature DB >> 26614989

Anti-TB drug resistance in Tanga, Tanzania: A cross sectional facility-base prevalence among pulmonary TB patients.

Abubakar S Hoza1, Sayoki G M Mfinanga2, Brigitte König3.   

Abstract

OBJECTIVE: To determine the prevalence and risk factors associated with drug resistance tuberculosis (TB) at facility-base level in Tanga, Tanzania.
METHODS: A total of 79 Mycobacterium tuberculosis (MTB) isolates included in the study were collected from among 372 (312 new and 60 previously treated) TB suspects self-referred to four TB clinics during a prospective study conducted from November 2012 to January 2013. Culture and drug susceptibility test of the isolates was performed at the institute of medical microbiology and epidemiology of infectious diseases, University hospital, Leipzig, Germany. Data on the patient's characteristics were obtained from structured questionnaire administered to the patients who gave informed verbal consent. Unadjusted bivariate logistic regression analysis was performed to assess the risk factors for drug resistant-TB. The significance level was determined at P < 0.05.
RESULTS: The overall proportions of any drug resistance and MDR-TB were 12.7% and 6.3% respectively. The prevalence of any drug resistance and MDR-TB among new cases were 11.4% and 4.3% respectively, whereas among previously treated cases was 22.2% respectively. Previously treated patients were more likely to develop anti-TB drug resistance. There was no association between anti-TB drug resistances (including MDR-TB) with the risk factors analysed.
CONCLUSIONS: High proportions of anti-TB drug resistance among new and previously treated cases observed in this study suggest that, additional efforts still need to be done in identifying individual cases at facility-base level for improved TB control programmes and drug resistance survey should continuously be monitored in the country.
Copyright © 2015 Hainan Medical College. Production and hosting by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Drug resistance; Facility-base; HIV; MDR-TB; Prevalence; Pulmonary tuberculosis

Year:  2015        PMID: 26614989     DOI: 10.1016/j.apjtm.2015.10.014

Source DB:  PubMed          Journal:  Asian Pac J Trop Med        ISSN: 1995-7645            Impact factor:   1.226


  5 in total

1.  Genotypic drug resistance using whole-genome sequencing of Mycobacterium tuberculosis clinical isolates from North-western Tanzania.

Authors:  Benson R Kidenya; Stephen E Mshana; Daniel W Fitzgerald; Oksana Ocheretina
Journal:  Tuberculosis (Edinb)       Date:  2018-02-21       Impact factor: 3.131

2.  Preservation of sputum samples with cetylpyridinium chloride (CPC) for tuberculosis cultures and Xpert MTB/RIF in a low-income country.

Authors:  Hellen Hiza; Basra Doulla; Mohamed Sasamalo; Jerry Hella; Lujeko Kamwela; Francis Mhimbira; Klaus Reither; Sebastien Gagneux; Levan Jugheli; Lukas Fenner
Journal:  BMC Infect Dis       Date:  2017-08-04       Impact factor: 3.090

3.  Differential yield of universal versus selective drug susceptibility testing of patients with tuberculosis in high-burden countries: a systematic review and meta-analysis.

Authors:  Anita Svadzian; Giorgia Sulis; Genevieve Gore; Madhukar Pai; Claudia M Denkinger
Journal:  BMJ Glob Health       Date:  2020-10

4.  TB or not TB? Definitive determination of species within the Mycobacterium tuberculosis complex in unprocessed sputum from adults with presumed multidrug-resistant tuberculosis.

Authors:  Peter M Mbelele; Elingarami Sauli; Emmanuel A Mpolya; Sagal Y Mohamed; Kennedy K Addo; Sayoki G Mfinanga; Scott K Heysell; Stellah Mpagama
Journal:  Trop Med Int Health       Date:  2021-06-24       Impact factor: 3.918

5.  Molecular Epidemiology of Mycobacterium tuberculosis Complex Strains in Urban and Slum Settings of Nairobi, Kenya.

Authors:  Glennah Kerubo; Perpetua Ndungu; Yassir Adam Shuaib; Evans Amukoye; Gunturu Revathi; Susanne Homolka; Samuel Kariuki; Matthias Merker; Stefan Niemann
Journal:  Genes (Basel)       Date:  2022-03-08       Impact factor: 4.096

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.